Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Poly(adenosine diphosphate-ribose) and ds-DNA binding activity have been measured in thirty-nine systemic lupus erythematosus (SLE) sera, nineteen rheumatoid arthritis sera, fourteen sera from non-SLE rheumatic and non-rheumatic diseases and in ten normal sera. Antibodies to poly(ADP-ribose) were found only in the SLE and in three SLE-like rheumatic diseases. Anti-DNA antibodies, on the other hand, were found not only in the SLE and SLE-like diseases, but also in rheumatoid arthritis and chronic active hepatitis. Estimation of poly(ADP-ribose) binding was, therefore, more specific for, and more discriminatory of SLE from other diseases, than the estimation of ds-DNA binding. The results indicate that the estimation of poly(ADP-ribose) binding in serum may be more useful in the diagnosis of SLE than the presently employed estimation of DNA binding using the Amersham kit. DNA-anti-DNA immune complexes are detected in some of the SLE sera after deoxyribonuclease I digestion, confirming earlier reports of the existence of circulating DNA-anti-DNA complexes in SLE patients. Snake venom phosphodiesterase treatment of some of the SLE sera also resulted in increased poly(ADP-ribose) binding activity, suggesting the existence of poly(ADP-ribose)-anti-poly(ADP-ribose) immune complexes in the circulation of SLE patients. This observation raises the possiblity that poly(ADP-ribose) immune complexes may play some part in the pathogenesis of some cases of SLE.
 ...
PMID:The significance of antibodies to poly(adenosine diphosphate-ribose) in systemic lupus erythematosus. 31 59

333 sera from 295 patients were tested for antinuclear antibodies (ANA) by indirect immunofluorescence, and for their binding capacities towards "native", double stranded DNA (anti-nDNA) by a commercially available radioassay kit. 63 out of 66 SLE sera were ANA positive, and 42 were anti-nDNA positive. 267 "non-SLE" sera were also tested, originating from patients with chronic aggressive hepatitis (77), rheumatoid arthritis (86), scleroderma (40), pseudo-LE syndrome (35), and various other "collagenous" diseases (29). 120 of these 267 sera were ANA positive, while only 16 (6%) gave elevated anti-nDNA values. Thus it appears that this anti-nDNA test kit is a helpful tool for the serological diagnosis of SLE.
 ...
PMID:[Diagnostic approaches in systemic lupus erythematosus (author's transl)]. 110 79

Anti double-stranded (ds) and single-stranded (ss) DNA IgG antibodies were detected in patients with various connective tissue diseases by RECOMBIGEN ELISA Anti ds-DNA Kit and ELISA Anti ss-DNA Kit (Nippon DPC Co) using E. coli plasmid DNA. High levels of anti ds-DNA and anti ss-DNA antibodies were mostly found and distributed in patients with systemic lupus erythematosus(SLE) and allied disorders. The sensitivity of Anti ds-DNA Kit was higher than that of current ELISA kit using calf thymus DNA antigen. In SLE patients with anti DNA antibodies sixty per cent of sera were reacted with both ds- and ss-DNA antigens, and forty per cent of sera were reacted only with ss-DNA antigen; there was no sample reacted positively with ds-DNA antigen alone. RECOMBIGEN ELISA Anti ds-DNA Kit and ELISA Anti ss-DNA Kit are highly sensitive and useful methods to detect anti ds- and/or ss-DNA IgG antibodies in patients with SLE.
 ...
PMID:[Clinical application of anti double-stranded and single-stranded DNA antibodies measurements by enzyme-linked immunosorbent assay (ELISA) using E. coli plasmid DNA]. 130 11

Antibodies to DNA are quite specific for systemic lupus erythematosus (SLE) and occur in the majority of SLE patients. Therefore, their detection is an important diagnostic aid to the clinician. Detection of anti-dsDNA may precede the diagnosis of SLE by more than a year. Fluctuations in the level of anti-dsDNA in an individual patient may give important information on the clinical status of the patient. Four of the most important methods developed for the measurement of anti-dsDNA antibodies will be discussed in this paper: the Farr assay, the PEG assay, the indirect immunofluorescence test on Crithidia luciliae and the ELISA. They will also be compared with one commercially available (Farr) assay, the Amersham anti-dsDNA kit. Each method, detects a part of the spectrum of anti-dsDNA antibodies produced by a patient. The Farr assay is the most specific for SLE; however, milder forms of the disease in which patients have only low avidity anti-dsDNA may easily be missed by this technique. Clinically, high avidity anti-dsDNA is related more frequently to the occurrence of nephritis, whereas low avidity anti-dsDNA antibodies are found more often in patients with central nervous system involvement. Traditionally, SLE is considered an immune-complex disease, in which inflammatory processes are initiated by local deposition of DNA/anti-dsDNA complexes. More recently, a major role was thought to be played by crossreactions of anti-dsDNA with tissue constituents. Our current view, however, is that such a crossreactivity plays only a minor role; we postulate that binding to glomerular constituents is caused by anti-dsDNA antibodies complexed with DNA and histones.
 ...
PMID:Anti-dsDNA: choice of assay in relation to clinical value. 175 10

The anti-native DNA antibodies were measured by a radioimmunoassay (RIA) type Farr assay in the sera from 648 patients: 108 with active or inactive systemic lupus erythematosus (SLE), 181 with clinical symptoms of another connective tissue disease, 171 with liver diseases, 29 with different pathology and 159 normal sera were obtained from a blood bank. The anti-DNA kit has been calibrated against the first international units/ml. This assay has proved to be sensitive and specific, and appears to be reliable for the diagnosis and follow-up of SLE patients. The authors propose a new reference cut-off level higher than producer's one.
 ...
PMID:[Evaluation of a radioimmunologic technique for the detection of anti-native DNA antibodies]. 192 49

Anti double-stranded DNA antibodies were detected in patients with various connective tissue diseases by using RECOMBIGEN Anti DNA kit (Japan DPC Co), newly developed utilizing highly purified double-stranded DNA obtained from E. coli plasmid by recombinant technique. High levels of anti double-stranded DNA antibodies were mostly found and distributed in patients with systemic lupus erythematosus and the allied disorders. Because of antibody excess, the final antibody titers could not be determined in most sera which had antibodies titers of more than 100 units per ml. In such sera the expression of antibody titer by DNA binding activities was found to be clinically more useful. RECOMBIGEN Anti DNA kit, thus, is a highly sensitive and reproducible method to detect anti double-stranded DNA antibodies.
 ...
PMID:[Detection of anti double-stranded DNA antibodies by RECOMBIGEN anti DNA kit]. 205 8

Anti-dsDNA is found in 60-70% of patients with active, untreated systemic lupus erythematosus (SLE) and its detection serves as an important tool in the diagnosis and monitoring of these patients. This study evaluates the use of an Enzyme Linked Immunosorbent Assay (Elisa) to detect these antibodies. Its performance is also compared to the older, but established, method of detecting anti-dsDNA using Crithidia luciliae. The sera of the 56 normal healthy blood donors revealed a mean anti-dsDNA titre of 0.93mg% with a standard deviation of 0.23mg%. All 14 patients found to be negative by the Elisa method and 10 of the 11 patients found to have borderline anti-dsDNA Elisa titres were negative by immunofluorescence. 35 patients were found to harbour raised titres of anti-dsDNA by the Elisa method. All patients found to have anti-dsDNA titres exceeding 2mg% by the Elisa test were also positive by immunofluorescence. In fact, those with very high titres by the Elisa test were also strongly (titre greater than 1:100) positive by immunofluorescence. As a measurement of the kit's accuracy, the percentage of recovery of the activity of known amounts of antibody in a specimen fell within the range of about 89-104%. As a measurement of the kit's reproducibility, the coefficient of variation in the assayed titres of sample replicates was found to be 7.5% for within-batch assays and 9.7% for between-batch assays. The Elisa assay compared favourably to the immunofluorescence test in terms of enhanced sensitivity, quantitative approach with an objective end-point and the large number of samples that may be assayed simultaneously.
 ...
PMID:Evaluation of an ELISA method for the measurement of antibodies to dsDNA. 268 35

An anti-C1q capture method kit (C1q-immunoglobulin G [IgG]) (Ortho Diagnostics, Inc., Raritan, N.J.) for measuring circulating immune complexes (CIC) was evaluated. The kit showed poor diagnostic sensitivity (P less than 0.005) for identifying CIC in patients with systemic lupus, rheumatoid arthritis, and bacterial endocarditis, as compared with polyethylene glycol-IgG and Raji cell tests (12, 24, and 24 positive, respectively, of 31 patients). Of the patients who were positive with the C1q-IgG test, 25% showed discrepancies when their results were compared with the polyethylene glycol-IgG and C1q-binding test results. Gel filtration chromatography of two of these discrepant sera showed the only peak of C1q-IgG activity to be associated with monomeric IgG (molecular weight, less than 200,000). We concluded that the kit method may be measuring substances other than CIC in some sera, because molecules of C1q attached to IgG should exhibit a molecular weight of greater than 500,000.
 ...
PMID:Evaluation of anti-C1q capture assay for detecting circulating immune complexes and comparison with polyethylene glycol-immunoglobulin G, C1q-binding, and Raji cell methods. 295 87

This paper announces the availability of the first international standard for anti-double-stranded DNA (anti-dsDNA). The material, coded Wo/80, was obtained after recalcification of plasma taken from a patient with systemic lupus erythematosus. Vials were filled with 500 microliters serum and freeze dried. The serum contains no other autoantibodies in measurable quantities. The vials should be stored at -20 degrees C. The standard should be used for establishing national, regional, or local standards. In eight laboratories satisfactory results with the immunofluorescence technique on Crithidia luciliae were obtained; the titres varied between 1/20 and 1/640 (mean 1/160). In seven laboratories the Farr assay, with the so called 'Amersham kit', was performed. At a dilution of 1:40 a mean binding percentage of about 50% was observed. After reconstitution with 500 microliters of distilled water, the vial contains 100 IU/500 microliters or 200 IU/ml. The standard can be obtained from the custodian of WHO: Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, PO Box 9190 1006 AD Amsterdam, The Netherlands.
 ...
PMID:The first international standard for antibodies to double stranded DNA. 305 22

We have studied the turnover of the third component of C (C3) and capture of the major cleavage fragment of C3 produced during C activation (C3b) that occurs when soluble antibody/DNA immune complexes (IC) active C. We used the Amersham RIA kit for the minor cleavage fragment of C3 produced during C activation (C3a), and a new assay utilizing mAb to C3b to measure the fraction of active C3 in a C source after the IC activate C. These mAb, along with a mAb to human IgG, allowed us to measure IC stoichiometries. The efficiency of C3 turnover by the IC is quite high, and under conditions of Ab excess, the maximum number of IgG bound per dsDNA corresponds to 1 IgG/20 to 30 base pairs. The maximum number of C3b found in the IC corresponds to less than 1 C3b/IgG, and the vast majority of the captured C3b is bound to the IgG, and not to the DNA. We identified several IC that consumed large amounts of C3, and captured large amounts of C3b, but did not bind to human E via C3b receptors (C receptor type 1). This finding suggests that the ability of IC to bind to human E depends upon the number and distribution of captured C3b molecules and the conformation and size of the DNA Ag, which reflects the need for multivalent binding between several properly arrayed C3b and a "cluster" of C receptor type 1 on the human E membrane. IC that activate C3 but do not bind to E would presumably "escape" the E IC clearance mechanism, but could deposit in susceptible organs and tissues and play a role in the pathogenesis of SLE because of their potential to generate the inflammatory products of C activation.
 ...
PMID:Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes. 319 18


1 2 3 4 5 6 7 8 9 10 Next >>